Johnson & Johnson Innovative Medicine company-sponsored congress materials which have been accepted for congress presentation at European Lung Cancer Conference

Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC Final Overall Survival from the Phase 3 MARIPOSA Study

Tremfya Dossier Update- docked

Rebranding

Submit your medical inquiry

Contact J&J Medical Connect for your medical inquiries


This page was last modified on

Additional contact #{index}

janssenscience

Congress Materials

Payer

oncology

amivantamab-plus-lazertinib-vs-osimertinib-video

Whitelist Modal

Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC Final Overall Survival from the Phase 3 MARIPOSA Study

Medical inquiries